Media Inquiries
For inquiries, please contact mediarelations@vyriad.com
November 12, 2021
Vyriad is developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence. I sat down for a fascinating conversation with Stephen Russell, Co-founder and CEO of Vyriad, to hear about this incredible technology and its potential to transform oncology treatment forever.
For inquiries, please contact mediarelations@vyriad.com